U.S. markets open in 6 hours 5 minutes
  • S&P Futures

    4,171.75
    -4.50 (-0.11%)
     
  • Dow Futures

    34,013.00
    -68.00 (-0.20%)
     
  • Nasdaq Futures

    14,038.00
    +8.50 (+0.06%)
     
  • Russell 2000 Futures

    2,251.40
    -7.60 (-0.34%)
     
  • Crude Oil

    62.87
    -0.26 (-0.41%)
     
  • Gold

    1,779.50
    -0.70 (-0.04%)
     
  • Silver

    25.92
    -0.18 (-0.69%)
     
  • EUR/USD

    1.1985
    +0.0004 (+0.04%)
     
  • 10-Yr Bond

    1.5730
    0.0000 (0.00%)
     
  • Vix

    16.25
    -0.32 (-1.93%)
     
  • GBP/USD

    1.3849
    +0.0010 (+0.07%)
     
  • USD/JPY

    108.4740
    -0.3090 (-0.28%)
     
  • BTC-USD

    57,089.02
    -362.30 (-0.63%)
     
  • CMC Crypto 200

    1,299.05
    -92.66 (-6.66%)
     
  • FTSE 100

    7,023.15
    +3.62 (+0.05%)
     
  • Nikkei 225

    29,685.37
    +2.00 (+0.01%)
     

Pharmaceutical ETFs Break Out on Horizon Pharma’s Positive Drug Results

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

This article was originally published on ETFTrends.com.

Pharmaceutical sector-related ETFs stood out Thursday after Horizon Pharma (HZNP) revealed positive test results for its treatment of thyroid eye disease, or TED.

Among the better performing non-leveraged ETFs of Thursday, the First Trust Nasdaq Pharmaceuticals ETF (FTXH) rose 1.8%, Invesco Dynamic Pharmaceuticals ETF (PJP) gained 1.5% and SPDR Pharmaceuticals ETF (XPH) increased 2.3%. Both FTXH and PJP were also testing their long-term resistance at the 200-day simple moving average.

Horizon Pharma shares surged 32.5% Thursday following the release of positive test results in its Phase 3 trial of its thyroid eye disease drug, teprotumumab, TheStreet reports.

HZNP makes up 4.0% of FTXH's underlying holdings, 3.0% of PJP's holdings and 2.6% of XPH.

According to the pharmaceutical company's reports, merely 83% of TED patients given teprotumumab had a "meaningful improvement in in proptosis, or bulging of the eye," the main cause of morbidity in the disease.

Horizon announced it will submit an application for a biologics license mid-year to the U.S. Food and Drug Administration for its proposed treatment of the thyroid eye disease. The company will also revealed detailed data later this year to a peer-reviewed journal and to a medical conference.

If the FDA approves teprotumumab, Horizon's new drug would be the first on the market to treat TED, a rare eye disease that afflicts as many as 20,000 people each year in the U.S.

A "progressive, debilitating autoimmune disease," TED can cause eye bulging, misalignment of the eyes, double vision and, in some cases, blindness, according to Horizon.

"The dramatic results of the teprotumumab Phase 3 confirmatory trial ... form a highly convincing body of clinical evidence supporting teprotumumab for the treatment of active thyroid eye disease," Timothy Walbert, chairman, president and CEO of Horizon, said in a note. "This is a key milestone as we evolve into a research-focused company."

For more information on the market sectors, visit our sector ETFs category.

POPULAR ARTICLES AND RESOURCES FROM ETFTRENDS.COM

READ MORE AT ETFTRENDS.COM >